Sunday, April 28, 2024
4/28/2024
Abstract Aicardi-Goutiéres syndrome (AGS) is a severe, often lethal genetic autoinflammatory encephalopathy. It typically has an infantile-onset and results in progressive and profound cognitive and physical disability. There is an urgent need to find an effective therapy for AGS, but currently, there is no FDA-approved therapeutic approach that effectively alters the pathological course of this disease. Clinical trials with IFN pathway inhibitors, such as the Janus kinase (JAK) inhibitors baricitinib and ruxolitinib, have been carried out in AGS; these JAK inhibitors reportedly resulted in improved systemic manifestations. However, their efficacies in treating brain injury, the most critical pathological change of AGS, are very limited or ineffective. There is a gap in AGS therapy development due to the relative rarity of this disease and not available of an animal model that recapitulates the pathologic features of AGS, especially the innate immune activation in the brain. We recently created a series of mouse models that reproduced AGS's genetic, clinical, and pathological features of the brain, including innate immune activation in the brain. With these AGS mouse models, we have found that the FDA very recently (2022) approved JAK inhibitor, the tyrosine kinase 2 (TYK2) inhibitor Deucravacitinib, and the TANK Binding Kinase 1 (TBK1) inhibitors sufficiently block innate immune activation in the brain cells of AGS mice. Based on our preliminary data and findings from recent publications, we hypothesize that selective inhibition of the type I IFN signaling pathway and TBK1 will more effectively diminish the innate immune activation in AGS brains and improve the outcomes of AGS treatment. In this study, we will address two Specific Aims. Specific Aim 1 is to test the efficacy of deucravacitinib and compare it with baricitinib and ruxolitinib to find which drug is the best medicine for AGS. Specific Aim two is to determine the significance of the JAK-STAT pathway in AGS development via analysis of Adar1mut and STAT1/2-/- double mutant mice and evaluate the effect of TBK1 inhibitor in mitigating neuroinflammatory phenotypes in AGS mouse models. In summary, this study will establish a preclinical approach in animal models to assess AGS therapy. It will provide in vivo evidence to support the repurposed use of JAK inhibitors for AGS treatment. It will also explore new drug-targeting sites for AGS and other interferonopathies.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
